Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies
Epithelial ovarian cancer is the most lethal gynecological malignancy. Due to its lack of symptoms, this disease is diagnosed at an advanced stage when the cancer has already spread to secondary sites. While initial rates of response to first treatment is >80%, the overall survival rate of pa...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2010-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/2/2/913/ |
| _version_ | 1797722431411978240 |
|---|---|
| author | Cécile Le Page David G. Huntsman Diane M. Provencher Anne-Marie Mes-Masson |
| author_facet | Cécile Le Page David G. Huntsman Diane M. Provencher Anne-Marie Mes-Masson |
| author_sort | Cécile Le Page |
| collection | DOAJ |
| description | Epithelial ovarian cancer is the most lethal gynecological malignancy. Due to its lack of symptoms, this disease is diagnosed at an advanced stage when the cancer has already spread to secondary sites. While initial rates of response to first treatment is >80%, the overall survival rate of patients is extremely low, mainly due to development of drug resistance. To date, there are no reliable clinical factors that can properly stratify patients for suitable chemotherapy strategies. Clinical parameters such as disease stage, tumor grade and residual disease, although helpful in the management of patients after their initial surgery to establish the first line of treatment, are not efficient enough. Accordingly, reliable markers that are independent and complementary to clinical parameters are needed for a better management of these patients. For several years, efforts to identify prognostic factors have focused on molecular markers, with a large number having been investigated. This review aims to present a summary of the recent advances in the identification of molecular biomarkers in ovarian cancer patient tissues, as well as an overview of the need and importance of molecular markers for personalized medicine in ovarian cancer. |
| first_indexed | 2024-03-12T09:47:14Z |
| format | Article |
| id | doaj.art-85b8f2b5fed04240ba06f5456593a91c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T09:47:14Z |
| publishDate | 2010-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-85b8f2b5fed04240ba06f5456593a91c2023-09-02T12:47:14ZengMDPI AGCancers2072-66942010-05-012291395410.3390/cancers2020913Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future StudiesCécile Le PageDavid G. HuntsmanDiane M. ProvencherAnne-Marie Mes-MassonEpithelial ovarian cancer is the most lethal gynecological malignancy. Due to its lack of symptoms, this disease is diagnosed at an advanced stage when the cancer has already spread to secondary sites. While initial rates of response to first treatment is >80%, the overall survival rate of patients is extremely low, mainly due to development of drug resistance. To date, there are no reliable clinical factors that can properly stratify patients for suitable chemotherapy strategies. Clinical parameters such as disease stage, tumor grade and residual disease, although helpful in the management of patients after their initial surgery to establish the first line of treatment, are not efficient enough. Accordingly, reliable markers that are independent and complementary to clinical parameters are needed for a better management of these patients. For several years, efforts to identify prognostic factors have focused on molecular markers, with a large number having been investigated. This review aims to present a summary of the recent advances in the identification of molecular biomarkers in ovarian cancer patient tissues, as well as an overview of the need and importance of molecular markers for personalized medicine in ovarian cancer.http://www.mdpi.com/2072-6694/2/2/913/gynecologic canceroutcomeimmunohistochemistry |
| spellingShingle | Cécile Le Page David G. Huntsman Diane M. Provencher Anne-Marie Mes-Masson Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies Cancers gynecologic cancer outcome immunohistochemistry |
| title | Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies |
| title_full | Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies |
| title_fullStr | Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies |
| title_full_unstemmed | Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies |
| title_short | Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies |
| title_sort | predictive and prognostic protein biomarkers in epithelial ovarian cancer recommendation for future studies |
| topic | gynecologic cancer outcome immunohistochemistry |
| url | http://www.mdpi.com/2072-6694/2/2/913/ |
| work_keys_str_mv | AT cecilelepage predictiveandprognosticproteinbiomarkersinepithelialovariancancerrecommendationforfuturestudies AT davidghuntsman predictiveandprognosticproteinbiomarkersinepithelialovariancancerrecommendationforfuturestudies AT dianemprovencher predictiveandprognosticproteinbiomarkersinepithelialovariancancerrecommendationforfuturestudies AT annemariemesmasson predictiveandprognosticproteinbiomarkersinepithelialovariancancerrecommendationforfuturestudies |